12 Health Care Stocks Moving In Tuesday’s Pre-Market Session
Gainers Viracta Therapeutics (NASDAQ:VIRX) stock increased by 16.8% to $0.68 during Tuesday’s pre-market session. The company’s market cap…
7 Analysts Assess Viridian Therapeutics: What You Need To Know
7 analysts have expressed a variety of opinions on Viridian Therapeutics (NASDAQ:VRDN) over the past quarter, offering a…
Here’s Why Viridian Therapeutics (VRDN) Stock Is Moving
Viridian Therapeutics shares are trading lower by 5.9% Thursday morning. The company announced pricing of an underwritten public offering.
Viridian Therapeutics Announces Proposed Underwritten Public Offering Of Common Stock And Preferred Stock; No Size Or Amount Disclosed
Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that it has commenced an
Viridian Therapeutics To Provide Key Updates On The Company’s Anti-Insulin-Like Growth Factor 1 Receptor Programs In Thyroid Eye Disease And Its Programs Targeting FcRn; VRDN-001 U.S. Annual Revenue ~$2B
Thyroid Eye Disease Portfolio: VRDN-001 and VRDN-003Intravenous VRDN-001Viridian's lead product candidate, VRDN-001, is a monoclonal antibody that acts as a full antagonist of IGF-1R, a clinically and commercially
ZimVie Agrees To Sell Its Spine Business, Joins United States Steel, PGT Innovations And Other Big Stocks Moving Higher On Monday
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 30 points on Monday.
Analyst Ratings for Viridian Therapeutics
Analysts have provided the following ratings for Viridian Therapeutics (NASDAQ:VRDN) within the last quarter: Bullish Somewhat Bullish Indifferent…
Where Viridian Therapeutics Stands With Analysts
Over the past 3 months, 7 analysts have published their opinion on Viridian Therapeutics (NASDAQ:VRDN) stock. These analysts…
Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday
U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session.
Viridian Therapeutics Appoints Stephen Mahoney As New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs And Announces $185M Private Placement Financing
– Stephen Mahoney appointed President and Chief Executive Officer –– Potential best-in-class subcutaneous and intravenous thyroid eye disease (TED) programs targeting insulin-like growth factor 1 receptor (IGF-1R) remain